

## NOXXON PHARMA AG TO PRESENT AT BIO CEO & INVESTOR CONFERENCE 2006 IN NEW YORK

Berlin, Germany, February 13, 2006 -- NOXXON Pharma AG (NOXXON), the next generation aptamer company and leader in Spiegelmer® therapeutics, will be presenting at the BIO CEO & Investor Conference, at 11:00 AM (US EST) on February 15<sup>th</sup> in the Park Avenue Suite Center/North at the Waldorf Astoria Hotel in New York.

Thomas Klein, Chief Executive Officer of NOXXON, will provide a corporate overview of NOXXON, including the current status of development of the company's next generation aptamers. "We are honoured to be invited to present at this event," stated Mr Klein. "The conference provides an ideal forum to present NOXXON's rapid development as well as exciting business opportunities for 2006. I am proud to substantiate this with a first product." Mr. Klein's presentation will be followed by a 30 minute breakout session.

## About the event:

The BIO CEO & Investor Conference is the world's leading biotechnology industry organization's forum to assemble senior level industry executives and key members of the investment community to explore investment and business development opportunities. For more information or a schedule of presentations visit: http://ceo.bio.org.

About NOXXON Pharma AG, the next generation aptamer company:

Based on one of the largest and best protected patent portfolio, Berlin-based NOXXON Pharma AG develops biostable aptamers, novel substances based on mirror image nucleic acids. These so-called Spiegelmers® (the German word "Spiegel" means mirror) bind highly specific to the pharmacologically relevant target for which they were selected. Thanks to their structural characteristics, Spiegelmers® are extremely resistant to degradation and not immunogenic - a new generation of improved therapeutics.

Website info: http://www.noxxon.net

General contact: Esther Brimacombe

NOXXON Pharma AG

Max-Dohrn-Strasse 8-10 10589 Berlin, Germany

Phone: + 49 30 72 62 47 0 FAX: + 49 30 72 62 47 225

Email: ebrimacombe@noxxon.net